



Coordination and redox properties of copper interaction with α -synuclein

This is a pre print version of the following article:

Original:

Valensin, D., Dell'Acqua, S., Kozlowski, H., Casella, L. (2016). Coordination and redox properties of copper interaction with α -synuclein. JOURNAL OF INORGANIC BIOCHEMISTRY, 163, 292-300 [10.1016/j.jinorgbio.2016.04.012].

Availability:

This version is available <http://hdl.handle.net/11365/1000423> since 2017-09-21T11:34:27Z

Published:

DOI:10.1016/j.jinorgbio.2016.04.012

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

This is the pre-print (submitted version) of:

Valensin D, Dell'Acqua S, Kozlowski H, Casella L. **Coordination and redox properties of copper interaction with α -synuclein**. J Inorg Biochem. 2016, 163, 292-300.

The final published version is available at: [10.1016/j.jinorgbio.2016.04.012](https://doi.org/10.1016/j.jinorgbio.2016.04.012)

Rights/License

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website

Coordination and Redox Properties of Copper Interaction with α -Synuclein

Daniela Valensin^{a*}, Simone Dell'Acqua^b, Henryk Kozlowski^c and Luigi Casella^{b*}

^a*Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A. Moro 2, 53100*

Siena, Italy

^b*Department of Chemistry, Università di Pavia, Via Taramelli 12, 27100 Pavia, Italy.*

^c*Faculty of Chemistry, University of Wrocław, F. Joliot-Curie 14, 50383 Wrocław, Poland*

Mail: daniela.valensin@unisi.it ; luigi.casella@unipv.it

Abstract

Parkinson's Disease (PD) is a severe neurodegenerative disorder affecting movements. After Alzheimer's disease, is the most common form of neurodegeneration. PD is characterized by the loss of neurons producing dopamine and by the presence of protein aggregates in the brain, known as Lewy body. The main constituent of Lewy body is the misfolded form of α -synuclein (α Syn), able to form oligomers and fibrils. In addition to protein aggregation, brain damage induced by oxidative stress is also a frequent phenomenon in PD. α Syn is able to bind Copper ions in both Cu(II) and Cu(I) oxidation states. The metal binding is also maintained when α Syn interacts with membranes. Interestingly, copper binding to α Syn has strong impact either in protein misfolding or in free radical formation, such to provide a link between protein aggregation and oxidative damage. In this review the role of copper and α Syn in PD is discussed with a particular emphasis to elucidate (i) the interaction between copper and α Syn; (ii) the reactivity and (iii) potential toxicity associated with copper- α Syn complexes.

1. Introduction

Copper, similarly to other transition metal ions, is an essential element for all living organisms. It is required for many cellular functions, such as metabolic processes and organ functions in humans. Human body has a sophisticated machinery that makes copper available when needed and, at the same time, eliminates copper when in excess. This complicated regulation, known as copper homeostasis, is ensured by a network of proteins and other biological molecules which take care of copper absorption, transport, distribution, storage and excretion [1-6]. Any failure of the homeostatic pathways leads to copper excess or deficiency in the body, which in turn, causes very serious diseases [7-10].

Copper has deleterious effects for neurodegenerative diseases as well [7, 8, 11-16]. The main effects are mediated by its redox properties and its ability to generate free radicals. In addition, copper is able to bind to proteins involved with neurodegeneration promoting their misfolding [17-19].

After Alzheimer's disease (AD), Parkinson's disease (PD) is the second most common form of neurodegeneration. As AD, PD is a progressive disorder characterized by damage and death of neurons. Similarly to AD, PD is correlated with high levels of oxidative stress, with the production of reactive oxygen species (ROS) and mitochondrial dysfunction [20-23]. Although possessing several similarities with AD, PD has different mechanisms, symptoms and treatments. In fact, the *substantia nigra* is the brain regions initially affected by PD, while the hippocampus and the entorhinal cortex are the areas primarily injured in AD. This explains the difference in observed symptoms, like movement and coordination impairments in PD and learning and memory impairments in AD. As for AD, no cure is available for PD so far.

The scientific community has put a lot of efforts for understanding the mechanisms associated with the disease onset and progression. In fact, their comprehension is crucial for a

rational drug design of new therapeutic agents. In this review the role of copper and α -synuclein (α Syn) in PD is discussed with a particular emphasis to elucidate (i) the interaction between copper and α Syn; (ii) the reactivity and (iii) potential toxicity associated with copper- α Syn complexes.

2. The synucleins and Parkinson's disease

PD is a devastating progressive neurodegenerative disease whose major clinical symptoms are tremor, movement impairments, postural instability, gait difficulty, and rigidity. It is characterized by the loss of dopaminergic neurons [24, 25] and by the presence of intracellular proteinaceous inclusions (Lewy bodies) mainly consisting of aggregated forms of the amyloidogenic protein α -synuclein (α Syn) [26-28].

α Syn is a 140 amino-acid protein, expressed within the central nervous system and concentrated at the presynaptic terminals of neuronal cells [29-32], where it can be found free in the cytosol or associated to synaptic vesicles or the mitochondrial membrane [33, 34]. Despite the evidence about the involvement of α Syn in neurodegeneration, its real function remains unknown. Three domains are identified along the protein sequence (Figure 1): (i) the amphipathic N-terminus (encompassing residues 1-60) which contains seven imperfect amino acid repeats involved in the interaction of the protein with lipid membranes and detergent micelles; (ii) the highly hydrophobic non amyloidogenic component (NAC, residues 61-95), that is responsible for protein-protein interaction during the aggregation process, and (iii) the acidic C-terminal region (residues 96-140), rich in Glu and Asp residues.

```
1  MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV
41 GSKTKEGVVH GVATVAEKTQ EQVTNVGGAV VTGVTAVAQK
81 TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP
121 DNEAYEMPS EEGYQDYEPEA
```

Figure 1. Primary sequence of α Syn. The three different domains are shown with different colours. Underlined amino acids represent copper anchoring sites.

α Syn is a non structured protein and it belongs to the class of “intrinsically disordered proteins” (IDP) [35, 36]. However, its N-terminal 100 residues region has high affinity for negatively charged lipids, and it undergoes a random coil to α -helix conformational transition upon interaction with lipid membranes and detergent micelles *in vivo* and *in vitro* (Figure 2) [37, 38].

The interaction of α Syn with membranes is involved in its physiological function *in vivo*, as well as in its misfolding and aggregation processes that is thought to be involved in the pathogenesis of Parkinson’s disease [39-48]. It has been observed that α Syn modulates presynaptic pool size and neurotransmitter release [49-53]. It has been recently suggested in fact that α Syn might act as a chaperone, promoting the rapid assembly of the SNARE complex involved in the neurotransmitter release from presynaptic vesicles [54]. All these functions are mediated by the interaction of α Syn with synaptic vesicles.




Figure 2. Schematic representation of structural transitions of α Syn after interacting with lipid membrane. α Syn cartoon showing the α -helix is derived from α Syn structure deposited in RCSC protein data bank PDB 1D 1XQ8 [38].

Soluble and insoluble fractions of Lewy bodies, extracted from brain tissues, contain α Syn (i) acetylated at the N-terminal group and (ii) phosphorylated at Ser129 [55, 56]. Only few years ago, Selkoe and coworkers pointed out that acetylation of α Syn is common in mammals [57]. From that point, extensive research has been conducted to evaluate the impact of N-terminal acetylation on

specific protein characteristics, such thermal stability, conformation, aggregation propensities, membrane interaction and metal binding [58-65]. The majority of the data support that acetylated α Syn (Ac- α Syn) has increased helical folding propensity, membrane binding affinity and resistance to aggregation.

α Syn has the propensity to misfold and aggregate [66] and, as stated above, α Syn oligomerization is considered a key event in the development of PD [67]. The formation of oligomers, fibrils and large aggregates is dependent on several factors, including protein overexpression, changes in pH, oxidative stress, interaction with dopamine and metal binding [68]. Protein oligomerization and fibrillation are strongly promoted by copper coordination to α Syn [18, 19]. On the contrary, Ac- α Syn-Cu(II) interaction results in minor oligomerization enhancement [62].

3. Copper- α -Synuclein Interaction

3.1 Cu(II) binding

The scientific community began to be interested in understanding Cu(II) binding to α Syn since 1999 when Paik et al. showed that protein oligomerization is induced by copper(II) ions [18]. Asp and Glu residues, abundantly present at the C terminus of α Syn, were identified as Cu(II) binding donors and a 59 μ M dissociation constant was measured [18]. From that point, a lot of investigations have been carried out to identify the metal binding properties of α Syn, as it is described in a number of recent reviews [13, 69, 70]. Several evidences have pointed out that the N-terminal region contains the highest affinity Cu(II) binding site, while the C-terminus acts as a weaker metal site [71-73]. Cu(II)- α Syn interaction at the N-terminus involves the amine and imidazole groups of Met1 and His50, respectively, which might behave as simultaneous (Figure 3A) or independent (Figure 3B) metal anchoring points. These different coordination modes were deduced by looking at the Cu(II) induced line broadening of NMR signals of various α Syn constructs. In the case of wild type α Syn, the most relevant effects were found at the N- and C- termini and His50 region. Conversely, two

diverse constructs, built to impair His50 binding, showed no consensus (Figure 3). The first one, where His50 is blocked by diethyl pyrocarbonate (DEPC) retains the paramagnetic effects only at the C-terminus (Figure 3A), while the other, having His50 substituted by Ala, still shows line broadening at the N-terminus (Figure 3B). These different behaviours might depend on (i) experimental conditions, such as pH and temperature, and (ii) the possibility that DEPC modifications occur on N-terminus as well, as previously demonstrated [72].




Figure 3. Proposed scheme of copper(II) binding region in α Syn according to the NMR paramagnetic effects measured on backbone signals (red regions). The comparison between A. wt α Syn and DEPC modified α Syn or B. wt α Syn and H50A α Syn are consistent with different binding domains.

ITC experiments also support the presence of two independent Cu(II) binding sites [73], α Syn1-9 (MDVFMKGLS) and α Syn48-52 (VAHGV) regions were identified as the strongest and independent metal binding domains (Figure 3B). The corresponding association constants (K_A) are

$5.9 \times 10^5 \text{ M}^{-1}$ and $7.5 \times 10^4 \text{ M}^{-1}$, respectively [73]. On the other hand, following ITC experiments on full length protein are consistent with stronger Cu(II) association, being the K_D values $0.11 \pm 0.01 \text{ } \mu\text{M}$ and $35.0 \pm 4.0 \text{ } \mu\text{M}$ for the the N-terminal and His50 binding sites, respectively [74].

Potentiometric and spectroscopic analysis performed on model peptides encompassing αSyn N-terminal residues, $\alpha\text{Syn}1-17$, $\alpha\text{Syn}1-28$ and $\alpha\text{Syn}1-39$, provided the first proof of the Cu(II) coordination sphere [75]. The most abundant species present at physiological pH is a 2N2O complex, where Cu(II) is bound to the amino terminal group of Met1, backbone amide nitrogen and carboxylate of Asp2, and a water molecule (Figure 4A). The complex is very stable, compared to other copper(II) complexes with 2N donor ligands, because of the involvement of Asp2 carboxylate and the formation of two adjacent five- and six-membered chelate rings. This binding mode is fully retained in all three peptides, independently of the length of the primary sequence. $\alpha\text{Syn}1-6$ sequence is the minimal copper(II) binding unit, as demonstrated by the structural model derived from NMR, CD and UV-Vis investigations [74].

In the perspective to better understand the role played by His50 in copper binding, a strong contribution is derived from investigations of Cu(II) coordination to peptide models containing both M1-D2- and -H50- residues [76]. The ligand was designed by starting from $\alpha\text{Syn}31-59$ sequence preceded by M29-D30 residues. At physiological pH, the 3N1O species is the predominant one. As shown in Figure 4B, His imidazole replaces the water molecule present in the coordination sphere of Cu(II) complexes [76].




Figure 4. Representation of the coordination sphere of Cu(II)- α Syn complexes. A. {2N2O} and B. {3N1O} binding modes.

The role played by His50 in Cu(II) binding was further evaluated by monitoring tryptophan fluorescence quenching upon metal interaction. To address this issue Phe4, Tyr39, Phe94 and Tyr125 were individually substituted by Trp in WT and H50S α Syn [77, 78]. Among all these constructs, fluorescence quenching is observed on F4W α Syn and F4W/H50S α Syn only, thus leading the authors to exclude any specific role of His50 in Cu(II) binding to the N-terminal region. However, it is important to point out that, compared to W4, which is very close to the N-terminus binding site, W39 and W94 are 11 and 44 residues far from His50, respectively. Therefore, by taking into account that no specific structural rearrangements of α Syn are observed upon Cu(II) coordination, these residues could be very far from the metal center, thus possibly explaining the unchanged Trp fluorescence on Y39W and F94W α Syn.

The involvement of His50 in the N-terminal copper binding site of α Syn is clearly demonstrated by EPR and ESEEM spectra which strongly support imidazole participation to the metal coordination sphere (Figure 4B) [79, 80]. In addition to those two binding modes, there is

evidence for an independent Cu(II) binding site located in the proximity of His50 region as well [80, 81]. This domain is much less effective in copper binding and it includes a 3N1O species. The three nitrogen donors are from His50 imidazole nitrogen and His50 and Val49 main chain nitrogens, while the oxygen ligand is from a bound water molecule [81].

His50 binding to Cu(II) is strongly dependent on pH, and it is completely lost at acidic pH values as observed with model peptides encompassing the N-terminal and His50 regions. Interestingly, these two anchoring points are able to form intermolecular species thus promoting aggregation and oligomerization [82]. Very similar conclusions are derived from investigations with a larger model peptide, α Syn1-56, supporting that copper(II), once anchored to either the N-terminus or His moieties acts as a bridge for two, three different protein molecules, illustrating how Cu(II) promote oligomerization and how close chain dimers or trimers are formed (Figure 5) [83].

His50 coordination to Cu(II) is completely lost in membrane bound α Syn, where copper binding is only at the N-terminus (Figure 4A) [84]. This behaviour is due to the fact that His50, being embedded in the α -helix structure, is less flexible and prone to reach the protein N-terminus. This is confirmed by the fact that TFE induced α helical conformations of wt α Syn and α SynS1-19 adducts as well, retain the Cu(II)-binding site at the N-terminus only [85].

As reported *above*, recent evidence revealed the existence of N-terminal acetylation of α Syn (Ac- α Syn) [57-64]. This post-translational modification completely removes the Cu(II) binding ability of the N-terminal region making all the data obtained previously less relevant from the biological point of view. In fact, as expected, no Cu(II) coordination anchoring points are available at the N-terminus, when the amino group of Met1 is acetylated. However, CD, ESI-MS and NMR investigations reveal that Ac- α Syn still interacts with Cu(II). The metal binding affinity is much lower and His50 and C-terminal regions are the preferred binding domains [61].




Figure 5. Illustration of α Syn dimer and trimer arrangement mediated by Cu(II) interaction. Adapted from figure 4 of reference 83.

3.2 Cu(I) binding

Compared to the plethora of studies with Cu(II), less data are available for the interaction between α Syn and Cu(I). The first evidence of Cu(I) binding to α Syn identifies the N-terminus as the major binding site for Cu(I) as well [86]. The binding donors are identified as the sulphur atoms of Met1 and Met5 thioether group, with an affinity in the micromolar range. Subsequent analysis point out that Cu(I) association can also occur at the C-terminus, where two additional thioether groups from Met116 and Met127 are able to bind the cuprous ion with similar binding affinity [87]. The two metal binding sites contain the $-M(X)_nM-$ motif which is well known for its ability to coordinate Cu(I) and Ag(I) ions, which is often used as probe for Cu(I) binding [88, 89]. The structural characterization of the two Cu(I) complexes, obtained by using model peptides reveals specific conformational

rearrangements, especially at the C-terminal region, where the hydrogen bonds between Ala124 HN and Asp121 CO, and between Met127 HN and Asp123 CO, stabilize a β -turn conformation [87]. The key role played by Met residues in Cu(I) coordination is further underlined by investigations on Met/Ile substituted α Syn complexes. A strong correlation between the number of Met groups coordinating the metal ion and Cu(I)- α Syn affinity is evident [90]. This behaviour is also clear from the analysis of Cu(I) interaction with α -synuclein (α Syn) [91].

The N-terminal regions of α Syn and β Syn are highly conserved, bearing just six point mutations, K10M, A27T, G31E, K45R, H50Q and T54S. Met at position 10 in β Syn provides a new thioether ligand for Cu(I) and increased metal binding affinity [91, 92]. In addition to the key role played by Met side chain in Cu(I) binding, recent EXAFS studies indicate that Asp2 carboxylate is also coordinated to Cu(I) in both α Syn and β Syn [91]. The structure of the Cu(I)- β Syn1-15 complex is shown in Figure 6. It is derived from the NOEs data measured for the peptide β Syn1-15 in presence of Ag(I) [91].




Figure 6. Superimposition of the first 15 structures obtained for the Ag(I)- β Syn1-15 complex. The structures are fitted on the 1-5 backbone residues with RMSD values for the backbone atoms 0.14 ± 0.08 Å. The sulfur donor atoms of Met-1, Met-5 and Met-10 are shown as yellow, cyan and green spheres, respectively. The carboxylic oxygen atoms of Asp-2 are shown as red spheres and the silver ion is shown as a grey sphere. Figure was created with MOLMOL 2K.1.0. Figure adapted from reference 91.

It is worth mentioning that Asp2 carboxylate is the only common donor atom of Cu(II) and Cu(I) coordination spheres. It may be speculated that the redox cycling between Cu(II)- α Syn and Cu(I)- α Syn is combined with a high reorganization energy due to the marked difference in the two coordination spheres. It is also possible that redox reaction is mediated by in-between states, as it occurs for Cu(II)-A β and Cu(I)-A β switch [93].

Finally, very recent investigations on Ac- α Syn indicate that Cu(I) binding is conserved in the acetylated protein as well. Contrary to what happens for Cu(II), acetylation of the amino group does not affect Cu(I) binding abilities. As for α Syn, Met1 and Met5 thioethers are identified as the copper(I) donor groups, with affinity in the micromolar range [94]. Interestingly, Cu(I) interaction with Ac- α Syn induces α helical rearrangement at the N-terminal region, which, on the contrary is not observed for amino free α Syn [94].





4. Reactivity of copper- α -synuclein complex

Copper concentration in living organisms is regulated by a sophisticated system of storage and transport proteins [95]. However, an imbalance of copper homeostasis is observed in neurodegenerative and prion diseases [96, 97]. This aspect is particularly important for Parkinson's disease in which copper may strongly affect the aetiology of the disease due to its possible interaction with α Syn, as described in the previous chapters of this review.

Besides assessing the structural features and the binding affinity it is important to evaluate the reactivity associated to the complexes that copper can form with α Syn in order to clarify their possible role in cell damage. In particular, the copper- α Syn interaction may influence the following processes, which are strongly interrelated: (i) to modulate the intrinsic redox reactivity of copper which can lead to the production of ROS, (ii) to promote the oxidation of external substrates present in the cell, (iii) to induce relevant post-translational modifications in α Syn itself.





The following reaction schemes are useful to address some general aspects of the redox reactivity of copper in this context.

- *Formation of ROS:*






where A_{red} is a reducing species present in the biological solution, such as ascorbate.

- *Pseudo-catecholase activity:*




- *Monoxygenase activity:*



where as before A_{red} is a reducing species and SH the substrate of the monoxygenase reaction.

- *Superoxide dismutase activity:*



The initial event occurring in reaction schemes 1-3 is the same, i.e. production of a reduced copper species, but the various mechanisms differ in the following reactivity of this species. In the ROS formation mechanism, the Cu(I) complex simply reacts with O_2 through an outer sphere

electron transfer, producing superoxide, which in turn will initiate a Fenton's reaction chain. In the other two reaction schemes, instead, formation of some copper-dioxygen complex is involved. Both CuO_2 and Cu_2O_2 types of dioxygen adducts are formed by mononuclear, non-coupled dinuclear, or dinuclear copper enzymes [98], and have been characterized in a number of synthetic mononuclear [99-101] and dinuclear copper complexes [102, 103]. Both types of copper-dioxygen adduct can promote oxidase and monooxygenase reactions, but the mononuclear CuO_2 adduct initially formed in the reaction between Cu(I) and O_2 , is not a strong oxidant and is generally assumed to evolve toward more reactive copper(II)-hydroperoxo or copper(III)-oxo species [104].

In reaction scheme 2, we refer to pseudo-catecholase activity because genuine catecholase activity implies two-electron oxidation of the substrate and does not proceed through the formation of semiquinone radicals [105]. In fact, both catechol oxidases and biomimetic copper complexes exhibiting such reactivity contain dinuclear metal centres [105, 106]. This situation is impossible to reproduce in the copper- αSyn complex, and in any copper complex with other neuronal peptides, because the peptide does not contain two proximal binding sites to host a pair of copper ions. It should also be added that both pseudo-catecholase and pseudo-monooxygenase activities can be promoted by ROS species produced by reaction scheme 1, although in this case it is expected that the reaction on the substrate will occur with lack of regioselectivity. For copper- αSyn , the pseudo-catecholase activity is of special importance, in view of the strong connection between the protein and dopamine in dopaminergic neurons.

In general, the studies reported so far with copper- αSyn were performed using the protein (usually expressed), or its peptide fragments, containing a free primary amine group at the N-terminal, whereas recent evidence shows that *in vivo* αSyn is N-acetylated in mammals [56, 107]. As explained in the "copper- $\alpha\text{-synuclein binding}$ " paragraph, αSyn N-acetylation abolishes the high affinity copper(II) coordination site [61], but it maintains the copper(I) coordination set unchanged

[94]. This implies that what is currently known about the redox properties and reactivity of the Cu(II)/Cu(I)- α Syn complexes needs to be revised and extended to the biologically relevant Cu(II)/Cu(I)-Ac- α Syn system. However, as data on the latter are scarce, here we will mostly focus on the extensive literature accumulated for copper bound to non-acetylated α Syn.

Lee *et al.* investigated the redox properties of copper- α Syn complex showing that Cu(II) can be reduced to Cu(I) under anaerobic conditions, whereas, in the presence of O₂, reoxidation of Cu(I) is associated with the generation of ROS, which can promote dityrosine cross-linking [108].

Zhou *et al.* showed that oxidation of Cu(I)- α Syn complex by atmospheric oxygen leads to the formation of hydrogen peroxide, which exhibits a cytotoxic behaviour [109]. However, a further study of the same group suggests that the conversion of unstructured α Syn to α -helical conformation reduces the production of ROS [85].

Further studies indicated that Cu(II)- α Syn can promote dopamine oxidation, in the presence of the reductive dye 3-methyl-2-benzothiazolinone hydrazone (MBTH), although the contribution of free copper to this reactivity was not investigated [110]. This study also showed that the reduction Cu(II)- α Syn with ascorbate produces hydroxyl radicals. In general, reactive catechols like dopamine and its metabolites, can exacerbate the toxicity effects of metal ions through redox reactions [111]. In addition, dopamine quinone itself has been reported to accelerate and stabilize the formation of cytotoxic α Syn protofibrils [112, 113].

This reactivity is important because there are several evidences that the amyloid aggregation process of α Syn is strongly affected by site-specific oxidation, dityrosine cross-linking and protein truncation [70, 114, 115]. The most important reaction is the oxidation of one of the four Met residues present in α Syn (Met1, Met5, Met116 and Met127), because this modification can inhibit amyloid fibril formation and promote the formation of stable α Syn oligomers [116-118]. The

oxidation of methionine residues also affects the membrane-binding properties of α Syn, by diminishing the affinity of α Syn to the membrane upon oxidation [119].

A study from Cappai *et al.*, shows that the incubation of Cu(II) - α Syn with dopamine leads to methionine sulfoxidation [120]. Moreover, oxidation of Met1 and Met5 at the N-terminal portion of α Syn can be easily promoted by the presence of copper(II) and hydrogen peroxide [116, 121, 122] or copper(II) and a reductant such as ascorbate [86]. A recent NMR study also shows that air exposure of the reduced Cu^I- α Syn complex leads to rapid oxidation of methionine residues [123]. Another oxidation sensitive residue is His50, which is oxidized in the presence of Cu(II) and H₂O₂ [122].

Recently, our group analysed the reactivity of copper(II)–peptide complexes, containing the N-terminal portion of α Syn bearing the minimal copper coordination unit, in oxidative reactions of catechols and phenols [124]. However, the copper– α Syn complex exhibits no significant tyrosinase-like reactivity, since its ability to promote phenol monooxygenase and diphenol oxidase reactions is lower than that of free copper(II). On the other hand, the superoxide dismutase reactivity (reaction scheme 4) of copper– α Syn complex is comparable to that of free copper.

We therefore concluded that the structural rearrangement in the metal coordination sphere required in Cu(II)/Cu(I) cycling prevents the copper– α Syn complex to be a good catalyst in reactions that involve dioxygen coordination to copper(I). However, our study confirms that redox cycling of Cu²⁺/Cu⁺ ions may cause concomitant modifications of α Syn through radical Fenton-like reactions.

An intriguing reactivity of Cu– α Syn is the interplay of this complex with iron homeostasis. Brown *et al.* proposed that α Syn can bind simultaneously copper(II) and iron(III), and that copper bound to the protein can act as an electron transfer centre between a donor such as NADH and an acceptor such as iron(III) [125, 126]. This ferrireductase reactivity could affect iron metabolism, which is also altered in PD pathogenesis.

5. Toxicity of copper- α -synuclein complex

The mechanism of α Syn toxicity is an actual challenge that is crucial for the elucidation of PD pathogenesis. Here, we intend to summarize the mechanisms that contribute to α Syn toxicity where the involvement of copper is demonstrated or hypothesized. As described in the previous paragraph, one of the most relevant relation between the formation of copper- α -synuclein and its toxicity is represented by post-translational modifications induced by metal-induced oxidative stress. This aspect is extremely important also because synucleinopathies and neurodegenerative diseases in general are associated with high levels of oxidative stress in the brain [115, 127, 128].

Methionine can be easily oxidised to sulfoxide *in vivo* by different oxidizing agents such as hydrogen peroxide, hypochlorite, chloramines and peroxynitrite. In the presence redox-active metal ions, the oxidation occurs in mild conditions, since it only requires e.g. copper in the cuprous state and molecular oxygen. However, the methionine sulfoxidation process is fine regulated under physiological conditions because in the cytosol several methionine sulfoxide reductases (Msr) are involved in the repair of methionine sulfoxidation (Figure 7) [115, 129]. Msr enzymes catalyse the reduction of oxidised methionines back to the sulfide form [130]. Two isoforms, Msr A and Msr B, are specific for reduction of the (*S*)-Met-SO and (*R*)-Met-SO enantiomers, respectively [131]. This has led to the hypothesis that α Syn may act as a catalytically regenerated oxidant scavenger in physiological conditions, thus performing an important protective role until this equilibrium is broken by an increase of oxidative stress.

On the other hand, further oxidation of methionine sulfoxide to sulfone leads to a final product that cannot be reduced by methionine sulfoxide reductases. This process is therefore irreversible within the cell and might have important consequences in the pathogenesis by contributing to the final state of the aggregation. *In vitro* experiments show that when α Syn is

incubated with reduced copper and oxygen the oxidation is limited to sulfoxide [123, 124], whereas the formation of sulfone is observed when also hydrogen peroxide is present [121, 122].




Figure 7. Schematic representation of the mechanism of oxidation and reduction of methionine residues in α Syn. In reducing environment copper can activate molecular oxygen to easily oxidize methionine residues to methionine sulfoxide. The reduction of methionine sulfoxide is catalyzed by methionine sulfoxide reductase (Msr). This enzyme uses the thioredoxin reductase (TrxR)-thioredoxin (Trx) system for its enzymatic redox cycle, which is a NADPH/NADP⁺ mediated process.

It is worth mentioning that other reactions are possible where copper ions can play a role. Nitration of tyrosine residues and dityrosine dimer formation are classical hallmarks of pathological conditions [132]. Human α Syn contains four tyrosine residues: one located in the N-terminal region at position 39 and three others in the C-terminal region, at positions 125, 133, and 136. An extensive literature confirms that the formation of nitrotyrosine has important consequences for α Syn toxicity [114, 115, 133-135]. In addition, another important post-translational modification involving tyrosine is the formation of dityrosine through aromatic ring coupling. Dityrosine formation has been observed upon oxidation of copper(I) and consequent formation of ROS (reaction scheme 1) [108].

How these nitrative and oxidative modifications influence the aggregation of α Syn to toxic oligomers is object of great debate and numerous studies have appeared [136], so that these aspects are outside the scope of the present review.

Phosphorylation of serine and tyrosine residues present in the C-terminal portion of α Syn is another relevant post-translational modification that has been extensively studied over the past years, albeit its neuroprotective vs. neurotoxic role is still object of debate [137]. The role of metal ions, and copper in particular, in this mechanism needs to be investigated more in detail, because phosphorylation of serine and tyrosine in the C-terminal seems to affect α Syn-metal interactions [138]. In particular, phosphorylation at Tyr-125 or Ser-129 residues increased the binding affinity of Cu(II), Pb(II), and Fe(II) to the protein, which provides evidence for the possible role of multiple interactions between α -synuclein and metal ions on the regulation of protein aggregation by its C-terminal.

A further issue is the involvement of copper into the interplay between α Syn and dopamine, because one of the physiological functions of α Syn is related to its involvement in dopamine metabolism and storage [139]. As explained in the previous chapter, we have shown that the oxidation of dopamine and other catechols is slower when the reaction is catalysed by copper- α Syn complex compared with free copper [124]. However, once the dopamine quinone is formed it leads to the formation of cytotoxic α Syn protofibrils [112, 113]. Also dopamine can bind to α Syn forming stable oligomers [140, 141], the toxicity of which is still debated [142-145].

Finally, another hypothesis regarding the relationship between copper homeostasis and PD pathogenesis is based on the evidence that total copper concentration in the pathogenic neurons affected by PD is decreased [146]. Some evidence suggests that a reduction of copper in neurons in PD can reduce the antioxidant defense related to superoxide dismutase (SOD1) [97]. These

observations might thus relate a loss of copper-dependent protective mechanisms to the neurodegenerative cascade.

6. Conclusions

Copper- α Syn interaction plays a crucial role in PD, because it influences various aspects of the pathophysiology of the protein, such as aggregation, accumulation, and induction of post-translational modifications.

Until recently, the effects of copper- α Syn interaction were studied in the frame of the high affinity binding of the Cu^{II} ion to the N-terminal portion of the protein. However, the finding that *in vivo* the α Syn terminal amino group is acetylated, dramatically decreasing the affinity for copper(II) [61], makes the model used so far of little use. On the other hand, the interest is now shifted to the interaction of the protein with Cu^{I} , as copper(I) coordination is not affected by N-terminal acetylation [94]. In particular, the reactivity of Cu^{I} -Ac- α Syn has to be better characterized.

Another general aspect of PD pathology that has received little attention so far is the spreading of α Syn oligomers in different brain areas. Protein propagation is common to other neurodegenerative diseases [147] and seems to involve an interplay between different amyloidogenic proteins. For instance, interaction between β -amyloid ($\text{A}\beta$) and α Syn [148] or between $\text{A}\beta$ and prion protein [149] appear to be relevant for Alzheimer's disease. Since all the proteins involved are able to bind copper, the metal ion and the associated redox reactivity might play an important role also in protein-protein interactions. We have recently reported the study of a copper-mediated interaction with truncated $\text{A}\beta$ 1-16 and α Syn1-15 peptides [92], that could be an important starting point for similar analysis with the full length proteins.

Finally, the role of membrane in the α Syn physiology and pathology needs to be further investigated. The structure of α Syn shifts from random coil to α -helix conformation upon interaction with lipid membranes and detergent micelles. More studies are therefore required to clarify this

“third” partner in the copper- α Syn relationship, because it certainly has an influence on the reactivity of copper-Ac- α Syn complexes.

Abbreviations

Parkinson’s Disease (PD)

α -synuclein (α Syn)

Alzheimer’s disease (AD)

reactive oxygen species (ROS)

non amyloidogenic component (NAC)

intrinsically disordered proteins (IDP)

acetylated α Syn (Ac- α Syn)

diethyl pyrocarbonate (DEPC)

Nuclear Magnetic Resonance (NMR)

Circular Dichroism (CD)

Ultraviolet-Visible (UV-Vis)

Electron Paramagnetic Resonance (EPR)

Electron spin echo envelope modulation (ESEEM)

trifluoroethanol (TFE)

electrospray ionisation mass spectrometry (ESI-MS)

extended X-ray absorption fine structure (EXAFS)

Nuclear Overhauser Effect (NOE)

3-methyl-2-benzothiazolinone hydrazone (MBTH)

methionine sulfoxide reductases (Msr)

Acknowledgements

We thank PRIN (Programmi di Ricerca di Rilevante Interesse Nazionale) (2010M2JARJ_004),

CIRMMP (Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine Para-magnetiche),

CIRCMSB (Consorzio Interuniversitario di Ricerca in Chimica dei Metalli nei Sistemi Biologici) for financial support.

References

1. L. Banci, I. Bertini, F. Cantini, S. Ciofi-Baffoni, *Cell. Mol. Life Sci.* 67 (2010) 2563-2589.
2. G. Crisponi, V.M. Nurchi, D. Fanni, C. Gerosa, S. Nemolato, G. Faa, *Coord. Chem. Rev.* 254 (2010) 876-889.
3. P. Palumaa, *FEBS Lett.* 587 (2013) 1902-1910.
4. N.J. Robinson, D.R. Winge, *Ann. Rev. Biochem.* 79 (2010) 537-562.
5. A. Gupta, S. Lutsenko, *Fut. Med. Chem.* 1 (2009) 1125-1142.
6. N.M.Hasan, S. Lutsenko, *Metal Transp.* 69 (2012) 137-161.
7. P. Dusek, T. Litwin, A. Czlonkowska, *Neurol. Clin.* 33 (2015) 175-204.
8. S.A. Bellingham, B. Guo, A.F. Hill, *Biol. Cell.* 107 (2015) 389-418.
9. A. Feldman, E. Aigner, D. Weghuber, K. Paulmichl *Biomed. Res. Int.* 2015 (2015) 287401.
10. S.G. Kaler, *Nat. Rev. Neurol.* 7 (2011) 15-29.
11. E. Gaggelli, H. Kozlowski, D. Valensin, G. Valensin, *Chem. Rev.* 106 (2006) 1995-2044.
12. D.B. Lovejoy, G.J. Guillemin, *Front Aging Neurosci.* 6 (2014) 173.
13. H. Kozlowski, M. Luczkowski, M. Remelli, Valensin, D., *Coord. Chem. Rev.*, 256 (2012) 2129-2141.
14. F. Molina-Holgado, R.C. Hider, A. Gaeta, R. Williams, P. Francis, *Biometals* 20 (2007) 639-654.
15. P. Dusek, P.M. Roos, T. Litwin, S.A. Schneider, T.P. Flaten, J. Aaseth, *J. Trace Elem. Med. Biol.* 31 (2015) 193-203.
16. E. Carboni, P. Lingor, *Metallomics* 7 (2015) 395-404.
17. V.N. Uversky, J. Li, A.L. Fink, *J. Biol. Chem.* 276 (2001) 44284-44296.
18. S.R. Paik, H.J. Shin, J.H. Lee, C. Chang, J. Kim, *Biochem. J.* 340 (1999) 821-828.

19. J. A. Wright, X. Wang, D.R. Brown, *FASEB J.* 23 (2009) 2384–2393.
20. M.T. Lin, M.F. Beal, *Nature* 443 (2006) 787–795.
21. S. Gandhi, A.Y. Abramov, *Oxid. Med. Cell. Longev.* 2012 (2012) 428010.
22. B. Halliwell, *Journal of Neurochem.* 97 (2006) 1634–1658.
23. B.J. Ryan, S. Hoek, E.A. Fon, R. Wade-Martins, *Trends Biochem. Sci.* 40 (2015) 200-210.
24. P. Jenner, *Ann. Neurol.* 53 (2003) S26-S36.
25. M. Ebadi, S.K. Srinivasan; M.D Baxi, *Prog. Neurobiol.* 48 (1996) 1-19.
26. J. Eriksen, T. Dawson, D. Dickson, L. Petrucelli, *Neuron.* 40 (2003) 453-456.
27. T. J. Gasser, *Neurol.* 248 (2001) 833-840.
28. M.G. Spillantini, M.L. Schmidt, V.M.Y. Lee, J.Q. Trojanowski, R. Jakes, M. Goedert, *Nature* 338 (1997) 839-840.
29. R. Jakes, M. G. Spillantini, M. Goedert, *FEBS Lett.* 345 (1994) 27-32.
30. P.J. Kahle, M. Neumann, L. Ozmen, V. Muller, H. Jacobsen, A. Schindzielorz, M. Okochi, U. Leimer, H. van Der Putten, A. Probst, E. Kremmer, H.A. Kretschmar, C.J. Haass *Neurosci.* 20 (2000) 6365-6373.
31. D.D. Murphy, S. M. Rueter, J. Q. Trojanowski, V.M. Lee, *J. Neurosci.* 20 (2000) 3214-3220.
32. M.C. Irizarry, T.W. Kim, M. McNamara, R.E. Tanzi, J.M. George, D.F. Clayton, B.T. Hyman, *J. Neuropathol. Exp. Neurol.* 55 (1996) 889-895.
33. D.F. Clayton, J.M. George, *J. Neurosci. Res.* 58 (1999) 120-129.
34. L. Maroteaux, J.T. Campanelli, R.H. Scheller, *J. Neurosci.* 8 (1988) 2804-2815.
35. V.N. Uversky, C.J. Oldfield, A.K. Dunker, *Annu. Rev. Biophys.* 37 (2008) 215-246.
36. C.W. Bertoncini, Y.S. Jung, C.O. Fernandez, W. Hoyer, C. Griesinger, T.M. Jovin, M. Zweckstetter, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005) 1430-1435.

37. C.C Jao, B.G. Hegde, J. Chen, I.S. Haworth, R. Langen, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 19666-19671.
38. T.S Ulmer, A. Bax, J. Biol. Chem. 280 (2005) 43179-43187.
39. N.B. Cole, D.D. Murphy, T. Grider, S. Rueter, D. Brasaemle, R.L. Nussbaum, J. Biol. Chem. 277 (2002) 6344–6352.
40. H.J. Lee, C. Choi, S.J. Lee, J. Biol. Chem. 277 (2002) 671-678.
41. J. Lotharius, P. Brundin, Nat. Rev. Neurosci. 3 (2002) 932–942.
42. M. Zhu, J. Li, A.L. Fink, J. Biol. Chem. 278 (2003) 40186–40197.
43. D.L. Fortin, M.D. Troyer, K. Nakamura, S. Kubo, M.D. Anthony, R.H. Edwards, J. Neurosci. 24 (2004) 6715–6723.
44. K. Vekrellis, H. J. Rideout, L. Stefanis, Mol. Neurobiol. 30 (2004) 1–21.
45. G.K. Tofaris, M.G. Spillantini Cell Mol. Life Sci. 64 (2007) 2194–2201.
46. D.P. Smith, D.J. Tew, A.F. Hill, S.P. Bottomley, C.L. Masters, K.J. Barnham, R. Cappai, Biochemistry 47 (2008) 1425–1434.
47. J.H. Soper, S. Roy, A. Stieber, E. Lee, R.B. Wilson, J.Q. Trojanowski, C.G. Burd, V.M. Lee, Mol. Biol. Cell. 19 (2008) 1093–1103.
48. C. Aisenbrey, T. Borowik, R. Byström, M. Bokvist, F. Lindström, H. Misiak, M.A. Sani, G. Gröbner, Eur. Biophys. J. 37 (2008) 247–255.
49. A. Iwai, E. Masliah, M. Yoshimoto, N. Ge, L. Flanagan, H.A. de Silva, A. Kittel, T. Saitoh, Neuron. 14 (1995) 467–475.
50. E. Masliah, A. Iwai, M. Mallory, K. Ueda, T. Saitoh, Am. J. Pathol. 148 (1996) 201–210.
51. Abeliovich A, Y. Schmitz, I. Fariñas, D. Choi-Lundberg, W.H. Ho, P.E. Castillo, N. Shinsky, J.M. Verdugo, M. Armanini, A. Ryan, M. Hynes, H. Phillips, D. Sulzer, A. Rosenthal, Neuron. 25 (2000) 239–252.

52. D.E. Cabin, K. Shimazu, D. Murphy, N.B. Cole, W. Gottschalk, K.L. McIlwain, B. Orrison, A. Chen, C.E. Ellis, R. Paylor, B. Lu, R.L. Nussbaum, *J. Neurosci.* 22 (2002) 8797–8807.
53. A.D. Gitler, B.J. Bevis, J. Shorter, K.E. Strathearn, S. Hamamichi, L.J. Su, K.A. Caldwell, G.A. Caldwell, J.C. Rochet, J.M. McCaffery, C. Barlowe, S. Lindquist, *Proc. Natl. Acad. Sci. USA* 105 (2008) 145–150.
54. J. Burré, M. Sharma, T. Tsetsenis, V. Buchman, M.R. Etherton, T.C. Sudhof, *Science* 329 (2010) 1663–1667.
55. J.P. Anderson, D.E. Walker, J.M. Goldstein, R. de Laat, K. Banducci, R.J. Caccavello, R. Barbour, J. Huang, K. Kling, M. Lee, L. Diep, P.S. Keim, X. Shen, T. Chataway, M.G. Schlossmacher, P. Seubert, D. Schenk, S. Sinha, W.P. Gai, T.J. Chilcote, *J. Biol. Chem.* 281 (2006) 29739–29752.
56. A. Ohrfelt, H. Zetterberg, K. Andersson, R. Persson, D. Secic, G. Brinkmalm, A. Wallin, E. Mulugeta, P.T. Francis, E. Vanmechelen, D. Aarsland, C. Ballard, K. Blennow, A. Westman-Brinkmalm, *Neurochem. Res.* 36 (2011) 2029–2042.
57. T. Bartels, J.G. Choi, D.J. Selkoe, *Nature* 477 (2011) 107–110.
58. L. Kang, G.M. Moriarty, L.A. Woods, A.E. Ashcroft, S.E. Radford, J. Baum, *Protein Sci.* 21 (2012) 911–917.
59. A.S. Maltsev, J. Ying, A. Bax, *Biochemistry* 51 (2012) 5004–13.
60. A.J. Trexler, E. Rhoades, *Protein Sci.* 21 (2012) 601–605.
61. T. Bartels, N.C. Kim, E.S. Luth, D.J. Selkoe, *PLoS One* 9 (2014) e103727.
62. G.M. Moriarty, C.A. Minetti, D.P. Remeta, J. Baum, *Biochemistry* 53 (2014) 2815–2817.
63. I. Dikiy, D. Eliezer, *J. Biol. Chem.* 289, (2014) 3652–3665.
64. B. Fauvet, M.B. Fares, F. Samuel, I. Dikiy, A. Tandon, D. Eliezer, H.A. Lashuel *J. Biol. Chem.* 287 (2012) 28243–28262.

65. G.M. Moriarty, M.K. Janowska, L. Kang, J. Baum, FEBS Lett. 587 (2013) 1128-1138.
66. E. Angot, J.A. Steiner, C.M. Lema Tomé, P. Ekström, B. Mattsson, A. Björklund, P. Brundin, PLoS One 7 (2012) e39465.
67. C.W. Olanow, P. Brundin, Parkinson's Movement Disorders 28 (2013) 31–40.
68. P. Cao, Y. Yuan, E.A. Pehek, A.R. Moise, Y. Huang, K. Palczewski, Z. Feng, PLoS One 5 (2010) e9312.
69. C. Migliorini, E. Porciatti, M. Luczkowski, D. Valensin, Coord. Chem. Rev. 256 (2012) 352-368.
70. A. Binolfi, L. Quintanar, C.W. Bertoncini, C. Griesinger, C.O. Fernández, Coord. Chem. Rev. 256 (2012) 2188-2201.
71. R.M. Rasia, C.W. Bertoncini, D. Marsh, W. Hoyer, D. Cherny, M. Zweckstetter, C. Griesinger, T.M. Jovin, C.O. Fernández, Proc. Natl. Acad. Sci. U S A 102 (2005) 4294-4299.
72. Y.H. Sung, C. Rospigliosi, D. Eliezer, Biochim. Biophys. Acta 1764 (2006) 5-12.
73. Bharathi, K.S. Rao, Biochem Biophys Res Commun. 359 (2007) 115-120.
74. A. Binolfi, E.E. Rodriguez, D. Valensin, N. D'Amelio, E. Ippoliti, G. Obal, R. Duran, A. Magistrato, O. Pritsch, M. Zweckstetter, G. Valensin, P. Carloni, L. Quintanar, C. Griesinger, C.O. Fernández, Inorg. Chem. 49 (2010) 10668-10679.
75. T. Kowalik-Jankowska, A. Rajewska, K. Wiśniewska, Z. Grzonka, J. Jezierska, J. Inorg. Biochem. 99 (2005) 2282-2291.
76. T. Kowalik-Jankowska, A. Rajewska, E. Jankowska, Z. Grzonka, Dalton Trans.42 (2006) 5068-5076.
77. J.C. Lee, H.B. Gray, J.R. Winkler, J. Am. Chem. Soc. 130 (2008) 6898-6899.
78. M.S. Jackson, J.C. Lee, Inorg. Chem. 48 (2009) 9303-9307.
79. C.G. Dudzik, E.D. Walter, G.L. Millhauser, Biochemistry 50 (2011) 1771-1777.

80. S.C. Drew, S.L. Leong, C.L. Pham, D.J. Tew, C.L. Masters, L.A. Miles, R. Cappai, K.J. Barnham, *J. Am. Chem. Soc.* 130 (2008) 7766-7773.
81. D. Valensin, F. Camponeschi, M. Luczkowski, M.C. Baratto, M. Remelli, G. Valensin, H. Kozlowski, *Metallomics* 3 (2011) 292-302.
82. R. De Ricco, D. Valensin, S. Dell'Acqua, L. Casella, P. Dorlet, P. Faller, C. Hureau, *Inorg. Chem.* 54 (2015) 4744-4751.
83. S.C. Drew, *Chemistry* 21 (2015) 7111-7118.
84. C.G. Dudzik, E.D. Walter, B.S. Abrams, M.S. Jurica, G.L. Millhauser, *Biochemistry* 52 (2013) 53-60.
85. B. Zhou, Y. Hao, C. Wang, D. Li, Y.N. Liu, F. Zhou, J. *Inorg. Biochem.* 118 (2013) 68-73.
86. A. Binolfi, A.A. Valiente-Gabioud, R. Duran, M. Zweckstetter, C. Griesinger, C.O. Fernandez, *J. Am. Chem. Soc.* 133 (2011) 194-196.
87. F. Camponeschi, D. Valensin, I. Tessari, L. Bubacco, S. Dell'Acqua, L. Casella, E. Monzani, E. Gaggelli, G. Valensin, *Inorg. Chem.* 52 (2013) 1358-1367.
88. H. Kozlowski, S. Potocki, M. Remelli, M. Rowinska-Zyrek, D. Valensin, *Coord. Chem. Rev.* 257 (2013) 2625-2638.
89. R. De Ricco, S. Potocki, H. Kozlowski, D. Valensin, *Coord. Chem. Rev.* 269 (2014) 1-12.
90. M.C. Miotto, A. Binolfi, M. Zweckstetter, C. Griesinger, C.O. Fernández, *J. Inorg. Biochem.* 141 (2014) 208-211.
91. R. De Ricco, D. Valensin, S. Dell'Acqua, L. Casella, E. Gaggelli, G. Valensin, L. Bubacco, S. Mangani, *Inorg. Chem.* 54 (2015) 265-272.
92. R. De Ricco, D. Valensin, S. Dell'Acqua, L. Casella, C. Hureau, P. Faller, *ChemBioChem* 16 (2015) 2319-2328.

93. L.E. Cassagnes, V. Hervé, F. Nepveu, C. Hureau, P. Faller, F. Collin, *Angew. Chem. Int. Ed. Engl.* 52 (2013) 11110-11113.
94. M.C. Miotto, A.A. Valiente-Gabioud, G. Rossetti, M. Zweckstetter, P. Carloni, P. Selenko, C. Griesinger, A. Binolfi, C.O. Fernández, *J. Am. Chem. Soc.* 137 (2015) 6444-6447.
95. I. Scheiber, R. Dringen, J.F. Mercer, *Met. Ions Life Sci.* 13 (2013) 359-387.
96. A.I. Bush, *Trends Neurosci.* 26 (2003) 207-214.
97. K.M. Davies, S. Bohic, A. Carmona, R. Ortega, V. Cottam, D.J. Hare, J.P. Finberg, S. Reyes, G. M. Halliday, J.F. Mercer, K.L. Double, *Neurobiol. Aging* 35 (2014) 858-866.
98. E.I. Solomon, D.E. Heppner, E.M. Johnston, J.W. Ginsbach, J. Cirera, M. Qayyum, M.T. Kieber-Emmons, C.H. Kjaergaard, R.G. Hadt, L. Tian, *Chem. Rev.* 114 (2014) 3659-3853.
99. T. Tano, Y. Okubo, A. Kunishita, M. Kubo, H. Sugimoto, N. Fujieda, T. Ogura, S. Itoh, *Inorg. Chem.* 52 (2013) 10431-10437.
100. R.L. Peterson, J.W. Ginsbach, R.E. Cowley, M.F. Qayyum, R.A. Himes, M.A. Siegler, C.D. Moore, B. Hedman, K.O. Hodgson, S. Fukuzumi, E.I. Solomon, K.D. Karlin, *J. Am. Chem. Soc.* 135 (2013) 16454-16467.
101. A. Conde, L. Vilella, D. Balcells, M.M. Díaz-Requejo, A. Lledós and P.J. Pérez, *J. Am. Chem. Soc.* 135 (2013) 3887-3896.
102. L.M. Mirica, X. Ottenwaelder, T.D.P. Stack, *Chem. Rev.* 104 (2004) 1013-1046.
103. S. Itoh, K.D. Karlin, *Copper-Oxygen Chemistry*, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2011.
104. N. Gagnon and W.B. Tolman, *Acc. Chem. Res.* 48 (2015) 2126-2131.
105. C. Gerdemann, C. Eicken, B. Krebs, *Acc. Chem. Res.* 35 (2002) 183-191.
106. G. Battaini, A. Granata, E. Monzani, M. Gullotti, L. Casella, *Adv. Inorg. Chem.* 58 (2006) 185-233.

107. B. Fauvet, M.K. Mbefo, M.B. Fares, C. Desobry, S. Michael, M.T. Ardah, E. Tsika, P. Coune, M. Prudent, N. Lion, D. Eliezer, D.J. Moore, B. Schneider, P. Aebischer, O.M. El-Agnaf, E. Masliah, H.A. Lashuel, *J. Biol. Chem.* 287 (2012) 15345-15364.
108. H.R. Lucas, S. Debeer, M.S. Hong, J.C. Lee, *J. Am. Chem. Soc.* 132 (2010) 6636-6637.
109. C. Wang, L. Liu, L. Zhang, Y. Peng, F. Zhou, *Biochemistry* 49 (2010) 8134-8142.
110. G. Meloni, M. Vašák, *Free Radic Biol Med* 50 (2011) 1471-1479.
111. T. Hasegawa, M. Matsuzaki-Kobayashi, A. Takeda, N. Sugeno, A. Kikuchi, K. Furukawa, G. Perry, M.A. Smith, Y. Itoyama, *FEBS Letters* 580 (2006) 2147-2152.
112. K.A. Conway, J.C. Rochet, R.M. Bieganski, P.T. Lansbury, Jr., *Science* 294 (2001) 1346-1349.
113. M. Bisaglia, L. Tosatto, F. Munari, I. Tessari, P.P. de Laureto, S. Mammi, L. Bubacco, *Biochem. Biophys. Res. Commun.* 394 (2010) 424-428.
114. C. Chavarría, J.M. Souza, *Arch. Biochem. Biophys.* 533 (2013) 25-32.
115. S. Schildknecht, H.R. Gerding, C. Karreman, M. Drescher, H.A. Lashuel, T.F. Outeiro, D.A. Di Monte, M. Leist, *J. Neurochem.* 125 (2013) 491-511.
116. N.B. Cole, D.D. Murphy, J. Lebowitz, L. Di Noto, R.L. Levine, R.L. Nussbaum, *J. Biol. Chem.* 280 (2005) 9678-9690.
117. W. Zhou, C. Long, S.H. Reaney, D.A. Di Monte, A.L. Fink, V.N. Uversky, *Biochem. Biophys. Acta* 1802 (2010) 322-330.
118. C.B. Glaser, G. Yamin, V.N. Uversky, A.L. Fink, *Biochem. Biophys. Acta* 1703 (2005) 157-169.
119. A.S. Maltsev, J. Chen, R. L. Levine, A. Bax, *J. Am. Chem. Soc.* 135 (2013) 2943-2946.
120. S.L. Leong, C.L. Pham, D. Galatis, M.T. Fodero-Tavoletti, K. Perez, A.F. Hill, C.L. Masters, F.E. Ali, K.J. Barnham, R. Cappai, *Free Radic. Biol. Med.* 46 (2009) 1328-1337.

121. T. Kowalik-Jankowska, A. Rajewska, E. Jankowska, K. Wisniewska, Z. Grzonka, J. Inorg. Biochem. 100 (2006) 1623-1631.
122. T. Kowalik-Jankowska, A. Rajewska, E. Jankowska, Z. Grzonka, Dalton Trans (2008) 832-838.
123. M.C. Miotto, E.E. Rodriguez, A.A. Valiente-Gabioud, V. Torres-Monserrat, A. Binolfi, L. Quintanar, M. Zweckstetter, C. Griesinger, C.O. Fernández, Inorg. Chem. 53 (2014) 4350-4358.
124. S. Dell'Acqua, V. Pirota, C. Anzani, M.M. Rocco, S. Nicolis, D. Valensin, E. Monzani, L. Casella, Metallomics 7 (2015) 1091-1102.
125. P. Davies, D. Moualla, D.R. Brown, PLoS ONE 6 (2011) e15814.
126. D.R. Brown, Biochem. Soc. Trans. 41 (2013) 1513-1517.
127. S.J. Dixon, B.R. Stockwell, Nat. Chem. Biol. 10 (2014) 9-17.
128. G. Exkici, P.H. Axelsen, Biochemistry 51 (2012) 6289-6311.
129. J. Moskovitz, Bioch, Biophys. Acta (BBA)-Proteins and Proteomics, 1703, (2005) 213-219.
130. F. Liu, J. Hindupur, J.L. Nguyen, K.J. Ruf, J. Zhu, J.L. Schieler, C.C. Bonham, K.V. Wood, V. J. Davisson, J.C. Rochet, Free Radic. Biol. Med. 45 (2008) 242-255.
131. B.C. Lee, V.N. Gladyshev, Free radical biology & medicine 50 (2011) 221-227.
132. H. Ischiropoulos, Arch. Biochem. Biophys. 484 (2009) 117-121.
133. C.Y. Chung, V. Khurana, P.K. Auluck, D.F. Tardiff, J.R. Mazzulli, F. Soldner, V. Baru, Y. Lou, Y. Freyzon, S. Cho, A. E. Mungenast, J. Muffat, M. Mitalipova, M.D. Pluth, N.T. Jui, B. Schuĕ, S.J. Lippard, L.H. Tsai, D. Krainc, S. L. Buchwald, R. Jaenisch, S. Lindquist, Science 242 (2013) 983-987.

134. R. Burai, N. Ait-Bouziad, A. Chiki, H.A. Lashuel, *J. Am. Chem. Soc.* 137 (2015) 5041-5052.
135. B.I. Giasson, J.E. Duda, I.V.J. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski, V.M.Y. Lee, *Science* 290 (2000) 985-989.
136. A.H.K. Tsang, K.K.K. Chung, *Bioch. Biophys. Acta* 1792, (2009) 643-650.
137. Y. Xu, Y. Deng, H. Qing, *J. Neurochem.* 135 (2015) 4-18.
138. Y. Lu, M. Prudent, B. Fauvet, H.A. Lashuel, H.H. Girault, *ACS Chem. Neurosci.* 2 (2011) 667-675.
139. H.A. Lashuel, C.R. Overk, A. Oueslati, E. Masliah, *Nat. Rev. Neurosci.* 14 (2013) 38-48.
140. C.L.L. Pham, N. Kirby, K. Wood, T. Ryan, B. Roberts, A. Sokolova, K.J. Barnham, C.L. Masters, R.B. Knott, R. Cappai, C.C. Curtain, A. Rekas, *Proteins: Structure, Function, and Bioinformatics* 82 (2014) 10-21.
141. O. Tavassoly, S. Nokhrin, O. Y. Dmitriev, J.S. Lee, *FEBS Journal* 281 (2014) 2738-2753.
142. S.L. Leong, M.G. Hinds, A.R. Connor, D.P. Smith, E. Illes-Toth, C.L.L. Pham, K.J. Barnham, R. Cappai, *PLoS ONE* 10 (2015) e0116497.
143. J. R. Mazzulli, M. Armakola, M. Dumoulin, I. Parastatidis, H. Ischiropoulos, *J. Biol. Chem.* 282 (2007) 31621-31630.
144. J. Li, M. Zhu, A.B. Manning-Bog, D.A. Di Monte and A.L. Fink, *FASEB J.* 18 (2004) 962-964.
145. Y. Ha, A. Yang, S. Lee, K. Kim, H. Liew, S.H. Lee, J.E. Lee, H.I. Lee, Y.H. Suh, H.S. Park, D. G. Churchill, *J. Neurosci. Res.* 92 (2014) 359-368.
146. S. Ayton, P. Lei, J. A. Duce, B. X. Wong, A. Sedjahtera, P.A. Adlard, A.I. Bush, D.I. Finkelstein, *Ann. Neurol.* 73 (2013) 554-559.

147. J. Brettschneider, K. Del Tredici, V.M.Y. Lee, J.Q. Trojanowski, *Nat. Rev. Neurosci.* 16 (2015) 109-120.
148. L. Crews, I. Tsigelny, M. Hashimoto, E. Masliah, *Neurotox. Res.* 16 (2009) 306-317.
149. H. You, S. Tsutsui, S. Hameed, T.J. Kannanayakal, L. Chen, P. Xia, J.D. Engbers, S.A. Lipton, P.K. Stys, G.W. Zamponi, *Proc. Natl. Acad. Sci. U S A.* 109 (2012) 1737-1742.